Clinical Trials Browser

Phase 2 × Dementia × 1 year × Clear all

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT06723015 2025-11-18

Tau PET Outcomes With Anti-amyloid Immunotherapies

Phase 2 Enrolling by invitation

135 enrolled

Lymphoid

Alzheimer Disease, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

Clinical Trials

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Tau PET Outcomes With Anti-amyloid Immunotherapies